ಇಂದು ವೃಶ್ಚಿಕ ರಾಶಿಯಲ್ಲಿ ಚಂದ್ರನ 12 ರಾಶಿಗಳ ಫಲಾಫಲ ಹೇಗಿದೆ..?
- Opko Health Inc said on Wednesday it signed a deal with Merck & Co Inc potentially worth up to $922.5 million for its experimental Epstein-Barr virus vaccine.
March 8 (Reuters) - Opko Health Inc said on
Wednesday it signed a deal with Merck Co Inc
potentially worth up to $922.5 million for its experimental
Epstein-Barr virus vaccine.
Shares of Opko jumped 28% in premarket trade.
Merck will take over the clinical and regulatory activities
related to the vaccine, as well its commercialization once the
drugmaker files a joint application with Opko unit ModeX
Therapeutics to test it in humans, the company said.
Opko will receive an upfront payment of $50 million and is
eligible for milestone payments of up to $872.5 million, plus
royalties on global sales.
There is currently no vaccine for the Epstein-Barr virus,
which is the leading cause of mononucleosis, or mono, commonly
called the "kissing disease".
(Reporting by Aditya Samal in Bengaluru; Editing by Pooja
Desai)